Intervention helps kids stay active after cancer treatment

Print Friendly, PDF & Email


Child with leukemia
Photo by Bill Branson
Results of a pilot study suggest a web-based, reward-driven intervention can motivate adolescent cancer survivors to stay physically active. Time spent performing moderate-to-vigorous physical activity (MVPA) increased by an average of 5 minutes a week for subjects who were randomized to the intervention. For control subjects,... [Read Article]
Print Friendly, PDF & Email

NK-cell therapy in resistant MDS, AML

Print Friendly, PDF & Email


Natural killer cell
destroying a cancer cell
Image by Joshua Stokes
Results of a phase 1/2 trial suggest treatment with haploidentical natural killer (NK) cells can be effective against relapsed/refractory myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). NK-cell therapy elicited responses in 6 of the 16 patients studied and provided a bridge... [Read Article]
Print Friendly, PDF & Email

Azacitidine now available in China

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
Azacitidine for injection (Vidaza®) is now available in China. The nucleoside metabolic inhibitor was approved in China to treat patients with intermediate-2/high-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) with 20% to 30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). Azacitidine for injection is marketed in... [Read Article]
Print Friendly, PDF & Email